Abstracts Archive - Page 2321 of 2607 - ACR Meeting Abstracts

Abstract Number: 1667 • 2013 ACR/ARHP Annual Meeting
Serum S100A8/S100A9 and S100A12 As a Marker Of Disease Activity In Giant Cell Arteritis
Jason Springer¹, Dirk Holzinger², Gary S. Hoffman³, Paul A. Monach⁴, Thomas Hamilton⁵, Carol A. Langford⁶, Dirk Foell⁷, David Cuthbertson⁸, Colin O'Rourke⁹, Simon Carette¹⁰, Nader A. Khalidi¹¹, Carol McAlear¹², Christian Pagnoux¹⁰, Philip Seo¹³, Kenneth J. Warrington¹⁴, Steven R. Ytterberg¹⁵, Thomas Vogl¹⁶, Peter A. Merkel¹⁷, Johannes Roth¹⁸ and Rula Hajj-Ali¹⁹, ¹Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Institute of Immunology, University Muenster, Muenster, Germany, ³Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁴Rheumatology, Boston University, Boston, MA, ⁵Cleveland Clinic, Cleveland, OH, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Department of Pediatric Rheumatology and Immunology, University of Münster, Münster, Germany, ⁸Department of Biostatistics, University of South Florida, Tampa, FL, ⁹Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ¹⁰Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹¹Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁶Institute of Immunology, University of Muenster, Muenster, Germany, ¹⁷Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ¹⁸Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ¹⁹Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: The S100 proteins (S100A8/9 complex and S100A12) are calcium binding proteins expressed during myeloid differentiation. S100 proteins are phagocyte-specific proteins that have been demonstrated…
Abstract Number: 1668 • 2013 ACR/ARHP Annual Meeting
Does Fibrinogen Have a Role In The Assessment Of Patients With Giant Cell Arteritis?
Lorraine O' Neill¹, Eoghan M. McCarthy², Anne M. Madigan³, Geraldine M. McCarthy⁴, Eamonn S. Molloy⁵, Ursula Fearon⁶, Douglas J. Veale⁵ and Conor Murphy⁷, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Rheumatology, Beaumont Hospital, Dublin, Ireland, ³Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁴Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁵Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁶Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ⁷Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) in the most common systemic vasculitis in patients over 50 years of age. Considerable difficulties exist in the evaluation of…
Abstract Number: 1669 • 2013 ACR/ARHP Annual Meeting
The Birmingham Vasculitis Activity Score As a Measure Of Disease Activity In Patients With Giant Cell Arteritis
Tanaz A. Kermani¹, David Cuthbertson², Simon Carette³, Gary S. Hoffman⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Kathleen McKinnon-Maksimowicz⁸, Carol McAlear⁹, Paul A. Monach¹⁰, Philip Seo¹¹, Kenneth J. Warrington¹², Steven R. Ytterberg¹³, Peter A Merkel¹⁴ and Eric L. Matteson¹⁵, ¹Rheumatology, University of California Los Angeles, Los Angeles, CA, ²Department of Biostatistics, University of South Florida, Tampa, FL, ³Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁵Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Internal Medicine, Salt Lake City Veterans Administration, Salt Lake City, UT, ⁷Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Rheumatology, Boston University, Boston, MA, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹³Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁴Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: To evaluate the performance of the Birmingham Vasculitis Activity Score (BVAS), a validated tool for assessment of vasculitis disease activity, in a cohort…
Abstract Number: 1670 • 2013 ACR/ARHP Annual Meeting
Large Vessel Vasculitis: Estimating Disease Activity In Patients With Inflammatory Thoracic Aortic Aneurysms
Alison Clifford¹, Tiffany M. Clark², Douglas Johnston³, Gosta Pettersson³, Eric Roselli⁴, E. Rene Rodriguez⁵, Edward Soltesz³, Lars Svensson⁴, Carmela Tan⁶ and Gary S. Hoffman¹, ¹Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ²Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ³Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, ⁴Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, ⁵Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH, ⁶Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Thoracic aortic aneurysms due to large vessel vasculitis may be a sign of ongoing inflammation or the sequelae of previous damage to the arterial…
Abstract Number: 1671 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Risk At Incidence Of Giant Cell Arteritis: A Population Based Retrospective Cohort Study
P. Deepak Udayakumar¹, Arun K. Chandran¹, Cynthia S. Crowson², Kenneth J. Warrington³ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Many systemic inflammatory rheumatic conditions are associated with increased cardiovascular (CV) risk. We aimed at assessing the CV risk at incidence of giant cell…
Abstract Number: 1672 • 2013 ACR/ARHP Annual Meeting
Serious Cardiovascular Events Risk Factors In Giant Cell Arteritis. A Population-Based Study In The French Apogee Cohort
Grégory Pugnet¹, Laurent Sailler², Guillaume Moulis³, Jean-Pascal Fournier⁴, Robert Bourrel⁵, Jean-Louis Montastruc⁶ and Maryse lapeyre-Mestre⁶, ¹Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ²Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, ³Clinical Pharmacology Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, France, ⁴Toulouse University, INSERM UMR 1027, Toulouse, France, ⁵Service Médical, Caisse Nationale de l'Assurance Maladie échelon régional, Midi-Pyrénées, Toulouse, France, ⁶Department of Clinical Pharmacology, Toulouse University Hospital, INSERM U1027, University of Toulouse, France, Toulouse, France
Background/Purpose: No population-based study has assessed serious cardiovascular events (sCVE) risk factors in Giant Cell Arteritis (GCA). The aim of our study was to identify…
Abstract Number: 1673 • 2013 ACR/ARHP Annual Meeting
Risk Of Myocardial Infarction In Patients With Giant Cell Arteritis: A Population-Based Study
Neda Amiri¹, Hyon K. Choi^2,3, Eric C. Sayre³, Kamran Shojania^3,4 and J. Antonio Avina-Zubieta^5,6, ¹University of British Columbia, Vancouver, BC, Canada, ²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ⁶Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Involvement of large arteries leading to stenosis is well-documented in giant cell arteritis (GCA), but limited data are available on the risk of coronary…
Abstract Number: 1674 • 2013 ACR/ARHP Annual Meeting
Acute Coronary Syndromes In Patients With Giant Cell Arteritis: A Population Based Retrospective Cohort Study
P. Deepak Udayakumar¹, Arun K. Chandran¹, Cynthia S. Crowson², Kenneth J. Warrington³ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Acute coronary syndrome (ACS) is one of the leading causes of death in the general population. We aimed at assessing the occurrence of ACS…
Abstract Number: 1675 • 2013 ACR/ARHP Annual Meeting
Infections Requiring Or Acquired During Hospitalizations In Patients With Giant Cell Arteritis – a Population Based Retrospective Cohort Study
P. Deepak Udayakumar¹, Arun K. Chandran¹, Cynthia S. Crowson², Kenneth J. Warrington³ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: There is a general impression that the patients with giant cell arteritis (GCA) on glucocorticoid therapy are at higher risk for infections. We aimed…
Abstract Number: 1676 • 2013 ACR/ARHP Annual Meeting
Statins Do Not Influence Occurrence Or Prednisone Requirement Of Giant Cell Arteritis. A French Population-Based Cohort Study
Grégory Pugnet¹, Laurent Sailler², Robert Bourrel³, Jean-Louis Montastruc⁴ and Maryse Lapeyre-Mestre⁴, ¹Toulouse University Hospital, Department of Internal Medicine, University of Toulouse, INSERM UMR 1027, Toulouse, France, ²Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, ³Service Médical, Caisse Nationale de l'Assurance Maladie échelon régional, Midi-Pyrénées, Toulouse, France, ⁴Department of Clinical Pharmacology, Toulouse University Hospital, INSERM U1027, University of Toulouse, France, Toulouse, France
Background/Purpose: Statins are widely prescribed to reduce the risk of cardiovascular ischemic events, but also present immunoregulatory effects promoting a shift from a TH-1 to…
Abstract Number: 1677 • 2013 ACR/ARHP Annual Meeting
May Giant Cell Arteritis Be Characterized By Different Clinical Entity and Long-Term Outcome?
Rosaria Talarico¹, Chiara Stagnaro², Claudia Ferrari³, Anna d'Ascanio⁴, Chiari Tani², Chiara Baldini², Marta Mosca³ and Stefano Bombardieri², ¹Rheumatology Unit, Pisa, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Italy, ³Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Malattie muscolo-scheletriche e cutanee, Rheumatology Unit, Pisa, Italy
Background/Purpose: Giant cell arteritis (GCA) represents the most common primary vasculitis of the elderly, that affect large and medium-sized arterial vessels. Growing data shown that…
Abstract Number: 1678 • 2013 ACR/ARHP Annual Meeting
How Similar Are Extracranial Giant Cell Arteritis and Takayasu Arteritis?
Tanaz A. Kermani¹, Cynthia S. Crowson², Francesco Muratore³, Jean Schmidt⁴, Eric L. Matteson⁵ and Kenneth J. Warrington⁶, ¹Rheumatology, University of California Los Angeles, Los Angeles, CA, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁴Internal Medicine and RECIF, CHU Nord, Amiens, France, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: The clinical and radiographic features of giant cell arteritis (GCA) with extracranial (large-vessel) involvement can be similar to those of Takayasu arteritis (TAK)…
Abstract Number: 1679 • 2013 ACR/ARHP Annual Meeting
Clinical Implications Of Antiphospholipid Antibodies In Takayasu’s Arteritis
Natasha Jordan¹, Holy Bezanahary¹ and David P. D'Cruz², ¹Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, ²Louise Coote Lupus Unit, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom
Background/Purpose: Takayasu’s arteritis (TA) is a granulomatous inflammation of unknown origin involving the aorta and its major branches. Association and implication of antiphospholipid antibodies (aPL)…
Abstract Number: 1680 • 2013 ACR/ARHP Annual Meeting
Predictivity Of Serum Biomarkers For Disease Activity In a Prospectively Followed-Up Takayasu Arteritis Cohort: Is Serum Amyloid A Protein Better Than Conventional Acute Phase Markers?
Ahmet Omma¹, Burak Erer², Nilufer Alpay³, Nuray Gurel Polat⁴, Ahmet Gul¹, Murat Inanc⁴, Lale Ocal¹ and Sevil Kamali¹, ¹Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Rheumatology Division, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Takayasu arteritis (TA) is a chronic vasculitis with an indolent course. Reliable diagnostic and activity markers have not yet been demonstrated. We aimed to…
Abstract Number: 1682 • 2013 ACR/ARHP Annual Meeting
Patients With TAKAYASU’S Arteritis Having Persistent ACUTE PHASE Response Usually Have An Increased MAJOR Vessel Uptake By 18F-FDG-PET/CT
Fatma Alibaz-Oner¹, Fuat Dede², Tunc Ones³, H.Turgut Turoglu² and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Nuclear Medicine, Marmara University, School of Medicine, Istanbul, Turkey, ³Nuclear Medicine, Marmara University, School of Medicine, ISTANBUL, Turkey
Background/Purpose: 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET/CT) is a sensitive imaging tool for large-vessel vasculitis. Although not uniformly accepted, an increased uptake by 18F-FDG PET/CT…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].